Lupin is a USD 2.06 billion innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 120,600 million (USD 2.06 billion) and Rs. 18,364 million (USD 393 million) respectively.

Company Growth (employees)
Mumbai, IN
Size (employees)
16,792 (est)+3%
Lupin was founded in 1968 and is headquartered in Mumbai, IN

Lupin Office Locations

Lupin has offices in Mumbai, Baltimore and Zug
Mumbai, IN (HQ)
Laxmi Towers BKC Road
Mumbai, IN
Highway House Jawaharlal Nehru Rd
Zug, CH
1 Landis + Gyr-Strasse
Show all (4)

Lupin Financials and Metrics

Lupin's Web-traffic and Trends

Lupin Online and Social Media Presence

Lupin News and Updates

Global Cephalosporin Market Scope, Share, Growth, Overview and Forecast to 2018 published “Cephalosporin Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Active Pharmaceutical Ingredients (API) Market 2018 Key Players: Albemarle Corporation, Aurobindo Pharma Limited, Boehringer Ingelheim GmbH, Lupin Pharmaceuticals Inc, Sun Pharmaceutical Industries LTD, Dr. Reddy’s Laboratories,. adds “Active Pharmaceutical Ingredients (API) Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database. Posted via Industry Today. Follow us on Twitter @IndustryToday

US drug approvals are through the roof—and Indian drugmakers are worried

Seven-hundred through, 300 more to go—the US Food and Drug Administration (USFDA) is doling out new drug approvals by the bag. That’s good news for…

FiercePharmaAsia—Pfizer’s China JV, Otsuka-Proteus’ digital pill, Astellas’ charity donations

Pfizer sold all of its 49% stake in a Chinese joint venture with Zhejiang Hisun Pharma, the FDA approved the U.S.’s first digital medicine by Otsuka and Proteus, Astellas joined a long list of industry big names under investigation for their copay charity donations, and more.

FiercePharmaAsia—Teva’s China JV? Lupin plants’ roadblock, EOC’s $32M series B

Teva is reportedly looking to form a Chinese joint venture, two of Lupin's plants were hit with a combined FDA warning letter, China's EOC Pharma has raised $32 million to help bring several cancer drugs to market and more.

Global Contraceptive Pills Market is expected to reach US$ 20.4 million by the end of the forecasted period 2016-2022

Contraceptive Pills market information, by drug class (Monophasic, Triphasic and Others) - Forecast to 2022 Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Lupin Company Life and Culture

You may also be interested in